Gestational Age, Birth Weight, and Treatment Timing in Infants Receiving Bevacizumab for Type 1 Retinopathy of Prematurity in Bangladesh

Purpose: To study gestational age (GA), birth weight (BW), and postmenstrual age (PMA) at intravitreal bevacizumab (IVB) treatment among infants with Type 1 retinopathy of prematurity (ROP) at a national tertiary eye hospital in Bangladesh. Methods: This retrospective descriptive study included 50 infants (83 treated eyes) who received IVB for Type 1 ROP at the National Institute of Ophthalmology and Hospital, Dhaka, from 1st January 2025 to 30 June 2025. Infant-level GA, BW, and PMA at injection were extracted from the ROP register. Postnatal age at injection was calculated as PMA minus GA. Continuous variables were summarized using mean (standard deviation [SD]) and median (interquartile range [IQR]); categorical thresholds were reported as frequencies and percentages. Spearman rank correlation assessed associations between birth characteristics and treatment timing. Results: Mean GA was 31.9 (SD 2.4) weeks and mean BW was 1,479 (SD 351) g. Median PMA at injection was 36 weeks (IQR 35–38; range 31–48), and median calculated postnatal age was 4 weeks (IQR 4–6.75; range 2–14). Twelve infants (24%) were born at ≥34 weeks, 18 (36%) weighed >1,500 g, and 5 (10%) weighed ≥2,000 g. PMA at injection correlated strongly with GA (Spearman ρ=0.740; p<0.001) and moderately with BW (ρ=0.400; p=0.004). Neither GA nor BW correlated with calculated postnatal age at injection (ρ=−0.031, p=0.831; and ρ=−0.104, p=0.474, respectively). Conclusions: Infants treated with bevacizumab for Type 1 ROP at this Bangladeshi tertiary center showed a broad maturity profile, including a substantial proportion of relatively mature and heavier infants. Treatment clustered around 35–38 weeks PMA, while later PMA treatment largely reflected greater GA at birth rather than longer postnatal time to treatment. These findings support locally inclusive screening pathways and systematic recording of disease phenotype and outcomes. J. Natl.Inst.Ophthalmol.2025;8(2): 20-24

Authors

Publication Details

Journal
Journal of National Institute of Ophthalmology
Published
2026-11-19
DOI
https://doi.org/10.3329/jnio.v8i2.95126
Primary Topic
Retinopathy of Prematurity Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Gestational Age, Birth Weight, and Treatment Timing in Infants Receiving Bevacizumab for Type 1 Retinopathy of Prematurity in Bangladesh

Mahamud Adnan, Mossammat Shoheli Nasrin, Md Iqram Ul Azam Khan, Md Abdur Rashid et al.
Journal of National Institute of Ophthalmology
Retinopathy of Prematurity Studies
article

Gestational Age, Birth Weight, and Treatment Timing in Infants Receiving Bevacizumab for Type 1 Retinopathy of Prematurity in Bangladesh

Mahamud Adnan, Mossammat Shoheli Nasrin, Md Iqram Ul Azam Khan, Md Abdur Rashid, Md Maksude Mowla, Md Sahidul Islam, Sohel Ahmed, Kamrun Nahar Beauty
article en

Abstract

Purpose: To study gestational age (GA), birth weight (BW), and postmenstrual age (PMA) at intravitreal bevacizumab (IVB) treatment among infants with Type 1 retinopathy of prematurity (ROP) at a national tertiary eye hospital in Bangladesh. Methods: This retrospective descriptive study included 50 infants (83 treated eyes) who received IVB for Type 1 ROP at the National Institute of Ophthalmology and Hospital, Dhaka, from 1st January 2025 to 30 June 2025. Infant-level GA, BW, and PMA at injection were extracted from the ROP register. Postnatal age at injection was calculated as PMA minus GA. Continuous variables were summarized using mean (standard deviation [SD]) and median (interquartile range [IQR]); categorical thresholds were reported as frequencies and percentages. Spearman rank correlation assessed associations between birth characteristics and treatment timing. Results: Mean GA was 31.9 (SD 2.4) weeks and mean BW was 1,479 (SD 351) g. Median PMA at injection was 36 weeks (IQR 35–38; range 31–48), and median calculated postnatal age was 4 weeks (IQR 4–6.75; range 2–14). Twelve infants (24%) were born at ≥34 weeks, 18 (36%) weighed >1,500 g, and 5 (10%) weighed ≥2,000 g. PMA at injection correlated strongly with GA (Spearman ρ=0.740; p<0.001) and moderately with BW (ρ=0.400; p=0.004). Neither GA nor BW correlated with calculated postnatal age at injection (ρ=−0.031, p=0.831; and ρ=−0.104, p=0.474, respectively). Conclusions: Infants treated with bevacizumab for Type 1 ROP at this Bangladeshi tertiary center showed a broad maturity profile, including a substantial proportion of relatively mature and heavier infants. Treatment clustered around 35–38 weeks PMA, while later PMA treatment largely reflected greater GA at birth rather than longer postnatal time to treatment. These findings support locally inclusive screening pathways and systematic recording of disease phenotype and outcomes. J. Natl.Inst.Ophthalmol.2025;8(2): 20-24

Journal of National Institute of OphthalmologyVol. 8(2)
Retinopathy of Prematurity Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon